Risk factor
Strong & resilient to price shocks
Profitability factor
Low dividends
About
Piramal Pharma Limited functions as a pharmaceutical enterprise, marketing a diverse array of pharmaceutical products and delivering specialized services, which encompass injectables and high-potency active pharmaceutical ingredient (HPAPI) production. Established in 2020, this company is headquartered in Mumbai, India, and operates as a subsidiary of Piramal Enterprises Limited.
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E, neutral on EV/EBITDA, re
Target Price
The average target price of PPLPHARMA.NS is 193 and suggests 17% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to